5-Amino-1MQ vs Cagrilintide

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

5-Amino-1-methylquinolinium (5-amino-1MQ) is a non-peptide small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM) as a methyl donor; NNMT is overexpressed in adipose tissue and has been identified as a metabolic regulator linking one-carbon metabolism, cellular methylation capacity, and adipogenesis. NNMT inhibition by 5-amino-1MQ is proposed to increase intracellular SAM and polyamine availability, shifting the cellular methylation balance in adipocytes toward suppression of adipogenesis and promotion of thermogenic gene expression; preclinical studies have examined effects on adipose tissue energy expenditure, systemic metabolism, and gut microbiome composition in diet-induced obesity mouse models. The best available indexed evidence is a preclinical study in diet-induced obese mice demonstrating that NNMT inhibition combined with caloric restriction altered microbiome composition and metabolic parameters; no human pharmacokinetic, safety, or efficacy data for 5-amino-1MQ has been published in any PubMed-indexed journal. 5-Amino-1MQ is a non-peptide research compound with no FDA approval or regulatory approval in any jurisdiction; it is not a peptide in the pharmacological sense and carries no human evidence base; all interest derives from preclinical metabolic data that has not been translated to human investigation. 5-Amino-1MQ dosage: No human clinical trial has established a dosing protocol for 5-Amino-1MQ. Preclinical research in rodent models has investigated this NNMT inhibitor at varying concentrations to assess metabolic effects. 5-Amino-1MQ is a research compound with no approved human dosing guidelines for any indication. Research protocols have explored oral and injectable delivery routes.

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

Cagrilintide is a long-acting synthetic amylin analogue under clinical development for obesity, designed to mimic the satiety-promoting and gastric-emptying-reducing actions of the endogenous beta-cell hormone amylin. By activating amylin receptors in the hindbrain, cagrilintide reduces caloric intake and body weight, and the drug is also being co-developed with the GLP-1 receptor agonist semaglutide (CagriSema) to target multiple appetite-regulating pathways simultaneously. Phase 2 randomized controlled trials published in The Lancet have demonstrated meaningful weight reduction in people with overweight and obesity, establishing proof of concept for both monotherapy and combination approaches. Cagrilintide is an investigational compound that has not yet received FDA approval; it remains in late-stage clinical development as of 2025.